Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 4/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.44 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.44 |
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.42 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.40 |
| ▸ | LPAR5 | Q9H1C0 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.39 |
| ▸ | PDE6D | O43924 | 1/20 | 0.39 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL60048 | 1.00 | HDAC3 (0.44) | HDAC3HDAC1HDAC2HDAC6NCOR2 | |
| SCHEMBL558413 | 0.86 | MEP1B (0.41) | HDAC1LTB4R2LPAR1 | |
| SCHEMBL558121 | 0.83 | NPC1 (0.38) | HDAC3HDAC1HDAC2HDAC6ALDH1A1 | |
| SCHEMBL557472 | 0.81 | HDAC1 (0.38) | HDAC3HDAC1HDAC2HDAC6NCOR2 | |
| SCHEMBL558113 | 0.81 | HDAC1 (0.38) | HDAC3HDAC1HDAC2HDAC6NCOR2 | |
| SCHEMBL557859 | 0.81 | HDAC1 (0.38) | HDAC3HDAC1HDAC2HDAC6NCOR2 | |
| SCHEMBL557865 | 0.81 | HDAC1 (0.38) | HDAC3HDAC1HDAC2HDAC6NCOR2 | |
| SCHEMBL10099778 | 0.81 | FOLH1 (0.42) | HDAC3HDAC1HDAC2HDAC6NCOR2 | |
| SCHEMBL10099782 | 0.81 | FOLH1 (0.42) | HDAC3HDAC1HDAC2HDAC6NCOR2 | |
| SCHEMBL34460422 | 0.79 | HDAC1 (0.52) | HDAC3HDAC1HDAC2HDAC6NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE46170-E1 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2016-10-04 | — | — | US | disclosed |
| US-RE46170-E1 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2016-10-04 | — | — | US | disclosed |
| US-RE46170-E1 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2016-10-04 | — | — | US | disclosed |
| CN-101133082-B | ACYLATED GLP-1 COMPOUNDS | NOVO NORDISK A/S (DK) | 2016-01-13 | — | — | CN | disclosed |
| EP-2322546-B1 | Acylated GLP-1 compounds | NOVO NORDISK AS (DK) | 2015-09-30 | — | — | EP | disclosed |
| CN-104402989-A | ACYLATED GLP-1 COMPOUNDS | NOVO NORDISK AS | 2015-03-11 | — | — | CN | disclosed |
| CN-104017062-A | Acylated GLP-1 compounds | NOVO NORDISK AS | 2014-09-03 | — | — | CN | disclosed |
| EP-1863521-B1 | EXTENDED GLP-1 COMPOUNDS | NOVO NORDISK AS (DK) | 2014-05-07 | — | — | EP | disclosed |
| US-8603972-B2 | Extended GLP-1 compounds | NOVO NORDISK A/S (DK) | 2013-12-10 | — | — | US | disclosed |
| EP-2256130-B1 | Novel insulin derivatives | NOVO NORDISK AS (DK) | 2013-09-25 | — | — | EP | disclosed |
| US-20080076705-A1 | Insulin Derivatives | NOVO NORDISK A/S (DK) | 2008-03-27 | — | — | US | disclosed |
| US-20080076705-A1 | Insulin Derivatives | NOVO NORDISK A/S (DK) | 2008-03-27 | — | — | US | disclosed |
| CN-101133082-A | Acylated GLP-1 compounds | NOVO NORDISK AS (DK) | 2008-02-27 | — | — | CN | disclosed |
| CN-101128214-A | Extended GLP-1 compounds | NOVO NORDISK AS (DK) | 2008-02-20 | — | — | CN | disclosed |
| EP-1863521-A1 | EXTENDED GLP-1 COMPOUNDS | Novo Nordisk A/S (DK) | 2007-12-12 | — | — | EP | disclosed |
| EP-1863839-A2 | ACYLATED GLP-1 COMPOUNDS | NOVO NORDISK A/S (DK) | 2007-12-12 | — | — | EP | disclosed |
| EP-1846446-A1 | INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006097537-A2 | ACYLATED GLP-1 COMPOUNDS | NOVO NORDISK A/S (DK) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006097538-A1 | EXTENDED GLP-1 COMPOUNDS | NOVO NORDISK A/S (DK) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006082204-A1 | INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076705-A1 | Insulin Derivatives | IAPP, INSR, GPR119 | HDAC3 360/4885HDAC1 1252/4885HDAC2 1821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.